The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Microsampling Approach for Monitoring of Kinase Inhibitor Targeted Therapies
Official Title: Development of a Microsampling Approach for Personalized Monitoring of Kinase Inhibitor Targeted Therapies
Study ID: NCT05598788
Brief Summary: The MISTIK project aims at clinically validating the technique of oral anticancer drugs determination by volumetric absorptive micro-sampling and at comparing the results to measurements performed on venous samples.
Detailed Description: The International recommendations for the validation of DBS-based methods will be applied (Capiau et al, TDM, 2019) by including 40 patients per molecule of interest. Nine drugs will be monitored : axitinib, olaparib, regorafénib, cabozantinib, niraparib, talazoparib, palbociclib, abemaciclib, tucatinib. Two samples will be collected from each patient, one by venous sampling and the second at the same time (approximately) using a capillary blood sample derived from a finger prick.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Centre Eugène Marquis Unicancer, Rennes, , France
Rennes University Hospital, Rennes, , France
Institut de cancérologie Strasbourg Europe, Strasbourg, , France
Name: VERDIER Marie-Clemence
Affiliation: Rennes University Hospital
Role: PRINCIPAL_INVESTIGATOR